Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2013-05-15

FDA Approved: PULMICORT RESPULES — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for Pulmicort RespuLes (budesonide) from AstraZeneca, resulting in labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pulmicort Respules (budesonide)

Snippet

SUPPL AP for PULMICORT RESPULES (BUDESONIDE)